CRISPR Therapeutics
Biotech · 9 tracked clinical trials
Clinical Pipeline
| Trial | Phase | Status | Indication |
|---|---|---|---|
| NCT04208529 | PHASE3 | ENROLLING_BY_INVITATION | Beta-Thalassemia, Thalassemia, Sickle Cell Disease |
| NCT05356195 | PHASE3 | ACTIVE_NOT_RECRUITING | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn |
| NCT05329649 | PHASE3 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance |
| NCT07549698 | PHASE1, PHASE2 | RECRUITING | Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia |
| NCT05643742 | PHASE1, PHASE2 | RECRUITING | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy |
| NCT07758634 | PHASE1, PHASE2 | RECRUITING | Hypertension |
| NCT06925542 | PHASE1 | RECRUITING | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis |
| NCT07491172 | PHASE1 | RECRUITING | Cardiovascular, Metabolic Disease, Dyslipidemias |
| NCT06208878 | — | ENROLLING_BY_INVITATION | Hematologic Malignancy, Solid Malignancy |
Partnerships & Collaborations
| Partner | Type | Announced | Details |
|---|---|---|---|
| Huidagene Therapeutics * | licensing | 2021-06-15 | Exclusive license agreement for Huidagene to develop and commercialize CTX001 (exagamglogene autotemcel) in Greater China. |
| Trucode Gene Repair * | acquisition | 2021-06-14 | Acquisition of Trucode Gene Repair to gain access to novel gene editing technologies complementary to CRISPR/Cas9. |
| ViaCyte * | collaboration | 2018-02-26 | Strategic collaboration to develop gene-edited stem cell-derived therapies for diabetes, combining ViaCyte's cell replacement platform with CRISPR/Cas9 gene editing. |
* Extracted from public news, pending verification.